Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CO5-C82E3 | Cynomolgus | Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified) |  |
|
|
| CO5-H5253 | Human | Human Complement C5 Protein, Fc Tag |  |
|
|
| CO5-H82E9 | Human | Biotinylated Human Complement C5 Protein, His,Avitag™ |  |
|
|
| CO5-R52H4 | Rabbit | Rabbit Complement C5 Protein, His Tag |  |
|
|
| CO5-H52H7 | Human | Human Complement C5 (w917s) Protein, His Tag (MALS verified) |  |
|
|
| CO5-H52Hx | Human | Human Complement C5 (R885H) Protein, His Tag |  |
|
|
| CO5-C52Hx | Cynomolgus | Cynomolgus Complement C5 Protein, His Tag |  |
|
|
| CO5-R52H5 | Rat | Rat Complement C5 Protein, His Tag |  |
|
|
| CO5-M52H4 | Mouse | Mouse Complement C5 Protein, His Tag |  |
|
|
| CO5-H52Ha | Human | Human Complement C5 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Human Complement C5 Protein, Fc Tag (Cat. No. CO5-H5253) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).
The purity of Biotinylated Cynomolgus Complement C5 Protein, His,Avitag (Cat. No. CO5-C82E3) is more than 85% and the molecular weight of this protein is around 170-210 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Avacincaptad pegol | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Macular Degeneration; Geographic Atrophy | Iveric Bio Inc, Astellas Pharma Inc | 2023-08-04 | Polypoidal choroidal vasculopathy; Wet Macular Degeneration; Geographic Atrophy; Macular Degeneration | Details |
| Zilucoplan Sodium | RA-101495-SC; RA-101495; ZLP-AI | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis | Details |
| Crovalimab | RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell | Details |
| Ravulizumab | ALXN-1210; ALXN-1810 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Respiratory Distress Syndrome, Adult; Amyotrophic Lateral Sclerosis; Acute Lung Injury; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Myasthenia Gravis; Thrombotic Microangiopathies; Heart Diseases; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Dermatomyositis | Details |
| Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Neuromyelitis Optica; Macular Degeneration; Kidney Failure, Chronic; Diabetes Mellitus; Urea Cycle Disorders, Inborn; Thrombocytopenia; Guillain-Barre Syndrome; Asthma; Glomerulonephritis, Membranoproliferative; Nasopharyngeal Carcinoma; Parturition; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; Rejection of renal transplantation; End Stage Liver Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome | Details |
| Pozelimab | REGN-3918 | Approved | Regeneron Pharmaceuticals Inc | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details |
| Eculizumab biosimilar (Amgen) | ABP-959 | Approved | Amgen Inc | BKEMV | United States | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Amgen Inc | 2024-05-28 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
| Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; AMT-904; SB12 | Approved | Samsung Bioepis Co Ltd | Epysqli, EPYSQLI | EU | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Samsung Bioepis Nl Bv | 2023-05-26 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
| Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
| Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | BIOCAD JSC | Hemoglobinuria, Paroxysmal | Details |
| Cemdisiran | ALN-CC5; AD-62643; ALN-62643; L96 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Myositis; Atypical Hemolytic Uremic Syndrome; Myositis, Inclusion Body; Geographic Atrophy; Macular Degeneration | Details |
| Nomacopan | EV-576; rEV-576; rVA576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Geographic Atrophy; Keratoconjunctivitis | Details |
| Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Novartis Pharma Ag, Morphosys Ag | Rejection of renal transplantation; Uveitis, Intermediate; Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Uveitis, Posterior; Panuveitis; Macular Degeneration | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| LP-005 | RX-001; LP-005 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Myasthenia Gravis; Peripheral Nervous System Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Amyotrophic Lateral Sclerosis | Details |
| Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
| Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
| IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
| ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
| RLYB-116 | RLYB-116 | Phase 1 Clinical | Rallybio Llc | Hematologic Diseases; Autoimmune Diseases; Immune System Diseases; Inflammation | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
| EA-5 | EA5; EA-5 | Phase 1 Clinical | Shanghai Lanyi Pharmaceutical Technology Co Ltd | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases | Details |
| eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
This web search service is supported by Google Inc.
A-Z
